0001415889-24-015041.txt : 20240531
0001415889-24-015041.hdr.sgml : 20240531
20240531161825
ACCESSION NUMBER: 0001415889-24-015041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240529
FILED AS OF DATE: 20240531
DATE AS OF CHANGE: 20240531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stalfort John A III
CENTRAL INDEX KEY: 0001709418
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 241009894
MAIL ADDRESS:
STREET 1: C/O ACUMEN PHARMACEUTICALS, INC.
STREET 2: 427 PARK STREET
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
FORMER NAME:
FORMER CONFORMED NAME: Stalfort Sean
DATE OF NAME CHANGE: 20170615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
form4-05312024_040510.xml
X0508
4
2024-05-29
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001709418
Stalfort John A III
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS
TX
75247
true
false
false
false
0
Common Stock
2024-05-29
4
A
0
49220
0
A
1098601
D
Common Stock
884290
I
See footnote
Stock Option (right to buy)
3.17
2024-05-29
4
A
0
98440
0
A
2034-05-29
Common Stock
98440
98440
D
Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact
2024-05-31